Arsenal Capital Partners, a prominent private equity firm based in New York, has announced the appointment of Stephen M. McLean as a Partner, significantly bolstering its healthcare investment capabilities. This strategic move underscores Arsenal’s commitment to the healthcare sector and its focus on partnering with experienced professionals to drive growth and value creation. Mr. McLean, a seasoned investor with a distinguished career in the healthcare industry, joins Arsenal’s established healthcare team to play a pivotal role in shaping investment strategies and leading the sourcing, evaluation, and management of key investments.
Mr. McLean brings to Arsenal Capital Partners a wealth of experience accumulated over 13 years as an active investor and board member in the healthcare arena. His focused expertise spans critical areas within healthcare, including life sciences, medical devices, and healthcare information services. Prior to joining Arsenal, Mr. McLean was a founding partner of Merrill Lynch Capital Partners and its successor funds, demonstrating his long-standing leadership and investment acumen in the financial sector.
Terrence Mullen, a Partner at Arsenal Capital Partners, highlighted the strategic importance of this appointment. “Steve’s exceptional track record in investing, leading, and building companies, combined with his deep expertise in the healthcare sector, makes him an invaluable addition to our team,” Mr. Mullen stated. He emphasized Arsenal’s long-term commitment to the healthcare sector since its inception in 2000 and expressed confidence that Mr. McLean’s caliber and industry network will significantly strengthen their operations. “Steve’s extensive industry network and domain knowledge are perfectly aligned with Arsenal’s strategy and model. His complementary expertise will further enhance our healthcare initiatives. Moreover, Steve is an excellent team player and a great fit for our organizational culture,” Mullen added.
Mr. McLean’s impressive portfolio includes his role as a founding investor and director of Agencourt Bioscience Corporation and Agencourt Personal Genomics. He also served as an investor and board member of Packard Bioscience Corporation, among other notable companies. Currently, he holds board positions in several healthcare companies, including Avantra Bioscience, RS Medical, and CentriHealth. Furthermore, Mr. McLean is Chairman of the International Biomedical Research Alliance, a private sector foundation supporting an advanced biomedical PhD program in collaboration with the National Institutes of Health, Oxford University, and Cambridge University. This demonstrates his commitment not only to investment but also to the advancement of biomedical research and education.
“For approximately 30 years, I have been investing in companies, and for nearly half of that time, I have been deeply involved with innovative healthcare companies focused on enhancing patient care efficacy and cost reduction,” Mr. McLean commented. He expressed his admiration for the Arsenal team and their shared strategic vision for investing in healthcare companies with significant growth potential, proven management teams, and leverageable products and technologies. “I am eager to collaborate with the Arsenal healthcare group and contribute to building successful and impactful businesses,” he concluded.
According to Mr. Mullen, Arsenal Capital Partners has a strong pipeline of investment opportunities within the healthcare sector, characterized by compelling business models. Mr. McLean’s expertise is expected to be instrumental in evaluating and capitalizing on these opportunities.
Before his successful career in private equity, including founding Merrill Lynch Capital Partners in 1984, Mr. McLean was a Managing Director at successor funds Stonington Partners and Arena Capital Partners. His career began in the Mergers & Acquisitions Department at Merrill Lynch in 1980. Mr. McLean holds an M.B.A. and a B.S. in Economics from the Wharton School of the University of Pennsylvania, further solidifying his robust foundation in finance and economics.
About Arsenal Capital Partners
Arsenal Capital Partners, headquartered in New York, is a private equity firm focused on investing in specialty industrial, healthcare, and financial services companies. Arsenal leverages its deep sector knowledge and operational expertise to partner with management teams and accelerate growth in businesses with significant value creation potential. With $800 million of committed equity capital, Arsenal is actively seeking and developing partnerships within its core sectors. For more information about Arsenal Capital Partners, please visit www.arsenalcapital.com.
Contact:
Chris Tofalli
Chris Tofalli Public Relations, LLC
914-834-4334
